title: Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3.
abstract: Lipoprotein glomerulopathy (LPG) is a rare disease, characterized by a special histology, including dilated glomerular capillaries filled with pale-stained and meshlike lipoprotein thrombi. It always presents with proteinuria or nephrotic syndrome. Although hyperlipidemia is not always seen, most patients have type III hyperlipoproteinemia with apolipoprotein (apo) E2/3 phenotyping. Although the clinical feature of LPG is rarely described, LPG associated with other glomerulopathy, including IgA nephropathy, membranous nephropathy, and lupus nephritis, has been documented. Until now, there have been no reports of psoriasis vulgaris associated with LPG. The authors present 2 cases of LPG with apo E3/3 genotyping associated with psoriasis vulgaris. The first patient was a 65-year-old woman who presented with nephrotic syndrome with daily urinary protein loss of 9.05 g and itchy erythematous scaly plaques on her trunk and lower limbs for 1 year. The renal biopsy results showed LPG, and the skin biopsy results showed psoriasis. The second patient was a 50-year-old man with history of psoriasis over his trunk and 4 limbs for 30 years. He also presented with nephrotic syndrome with daily urinary protein loss of 7.55 g. The renal biopsy results also showed LPG. The genotype of apo E showed E3/3, and lipoprotein electrophoresis showed a type III hyperlipoproteinemia-like pattern in both cases. The authors suggest that presence of apo E3/3 genotype cannot rule out the diagnosis of type III hyperlipoproteinemia and LPG. Besides, LPG should be included in the differential diagnosis of psoriatic patients with nephrotic syndrome, especially in Asian patients who show poor response to traditional therapy. Renal biopsy should be performed to make the definitive diagnosis.
authors.affiliation: Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taiwan, China.
authors.forename: Chao-Fu
authors.initials: CF
authors.lastname: Chang
authors.forename: Chih-Ching
authors.initials: CC
authors.lastname: Lin
authors.forename: Jinn-Yang
authors.initials: JY
authors.lastname: Chen
authors.forename: An-Hang
authors.initials: AH
authors.lastname: Yang
authors.forename: Ming-Shi
authors.initials: MS
authors.lastname: Shiao
authors.forename: Jau-Tsuen
authors.initials: JT
authors.lastname: Kao
authors.forename: Wu-Chang
authors.initials: WC
authors.lastname: Yang
mesh_terms: D000368:Aged; D053318:Apolipoprotein E3; D001057:Apolipoproteins E / Q000235:genetics / Q000378:metabolism*; D004487:Edema / Q000209:etiology; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000097:blood / Q000150:complications* / Q000235:genetics; D007674:Kidney Diseases / Q000209:etiology* / Q000235:genetics / Q000378:metabolism; D007678:Kidney Glomerulus / Q000473:pathology*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000209:etiology; D011507:Proteinuria / Q000209:etiology; D011565:Psoriasis / Q000150:complications*
chemical_list: D053318:Apolipoprotein E3; D001057:Apolipoproteins E; D008079:Lipoproteins, VLDL